6 completed, 1 unknown. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 3 | Completed 2, Unknown 1 |
Follow GSK372475: new trials by email Literature Review of GSK372475 trials Research Report on GSK372475
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial Of NS2359 For The Treatment of Cocaine Dependence NS2359, placebo - Cocaine Use Disorder | Phase 2 | Completed | University of Pennsylvania | 55 | 2016-05-01 | 2021-05-24 |
| GSK372475 PK Study in Healthy Volunteers GSK372475 - Depressive Disorder | Phase 1 | Completed | GlaxoSmithKline | 66 | 2008-07-28 | 2017-07-13 |
| GSK372475 Bioequivalence Study GSK372475 - Healthy Subjects, Depressive Disorder | Phase 1 | Completed | GlaxoSmithKline | 66 | 2007-07-01 | 2012-06-04 |
| A Study Of New Medicine (GSK 372475) For The Treatment Of Depression GSK372475, venlafaxine, placebo - Depressive Disorder | Phase 2 | Completed | GlaxoSmithKline | 396 | 2007-04-01 | 2014-10-10 |
| MDD POC Study GSK372475 Subjects Depressive Disease GSK372475, Paroxetine, Placebo - Depressive Disorder | Phase 2 | Completed | GlaxoSmithKline | 492 | 2006-12-19 | 2018-02-05 |
| Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder NS2359, Placebo - Attention Deficit Hyperactivity Disorder | Phase 2 | Completed | NeuroSearch A/S | 126 | 2003-08-01 | 2007-04-30 |
| Drug Interaction Study With NS2359 and Cocaine in Cocaine Experienced Volunteers - 1 NS2359 - Cocaine-Related Disorders, Drug Administration Schedule | Phase 1 | Unknown | National Institute on Drug Abuse (NIDA) | 24 | 2001-06-01 | 2017-01-11 |
Depressive Disorder (4) · Depressive Disorder, Major (2) · Attention Deficit Disorder with Hyperactivity (1) · Cocaine-Related Disorders (1)
GlaxoSmithKline (4) · National Institute on Drug Abuse (NIDA) (1) · NeuroSearch A/S (1) · University of Pennsylvania (1)
Canada (3) · Germany (3) · United States (3) · Bulgaria (2) · France (2) · India (2) · Poland (2) · Australia (1) · Belgium (1) · Chile (1) · Costa Rica (1) · Croatia (1) · Estonia (1) · Finland (1) · Italy (1)
Louis Cantilena, M.D. (1) · Thimothy Wilens, MD (1) · Wade Berrettini, MD, PhD (1)